Patterns of multispecialty care for low- and intermediate-risk prostate cancer in the use of active surveillance

被引:0
|
作者
Zambrano, Ibardo A. [1 ]
Hwang, Soohyun [2 ]
Basak, Ram [1 ]
Spratte, Brooke Namboodri [1 ]
Filson, Christopher P. [3 ]
Jacobs, Bruce L. [4 ]
Tan, Hung-Jui [1 ]
机构
[1] Univ N Carolina, Dept Urol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Hlth Policy & Management, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA
[3] Emory Univ, Dept Urol, Sch Med, Atlanta, GA USA
[4] Univ Pittsburgh, Dept Urol, Pittsburgh, PA USA
关键词
Prostate cancer; Active surveillance; SEER Medicare; Multispecialty care; Referral; Consultation; MODULATED RADIATION-THERAPY; UROLOGISTS; RECOMMENDATIONS; ONCOLOGISTS;
D O I
10.1016/j.urolonc.2023.04.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Multidisciplinary models of care have been advocated for prostate cancer (PC) to promote shared decision-making and facilitate quality care. Yet, how this model applies to low-risk disease where the preferred management is expectant remains unclear. Accordingly, we examined recent practice patterns in specialty visits for low/intermediate-risk PC and resultant use of active surveillance (AS). Methods: Using SEER-Medicare, we ascertained whether patients saw urology and radiation oncology (i.e., multispecialty care) versus urology alone, based on self-designated specialty codes, for newly diagnosed PC from 2010 to 2017. We also examined the association with AS, defined as the absence of treatment within 12 months of diagnosis. Time trends were analyzed using Cochran-Armitage test. Chi squared and logistic regression analyses were applied to compare sociodemographic and clinicopathologic characteristics between these models of care. Results: The proportion of patients seeing both specialists was 35.5% and 46.5% for low- and intermediate-risk patients respectively. Trend analysis showed a decline in multispecialty care in low-risk patients (44.1% to 25.3% years 2010-2017; P < 0.001). Between 2010 and 2017, the use of AS increased 40.9% to 68.6% (P < 0.001) and 13.1% to 24.6% (P < 0.001) for patients seeing urology and those seeing both specialists respectively. Age, urban residence, higher education, SEER region, co-morbidities, frailty, Gleason score, predicted receipt of multispecialty care (all P < 0.02). Conclusions: Uptake of AS among men with low-risk PC has occurred primarily under the purview of urologists. While selection is certainly at play, these data suggest that multispecialty care may not be required to promote the utilization of AS for men with low-risk PC. 0 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:388.e1 / 388.e8
页数:8
相关论文
共 50 条
  • [21] Is active surveillance safe for patients with intermediate-risk prostate cancer?
    Chung, Hoseok
    Shin, Bo Sung
    Nam, Deok-Hyun
    Chung, Hoseok
    Kim, Myung Ki
    Jung, Seung Il
    Kang, Taek Won
    Kwon, Dong Deuk
    BJU INTERNATIONAL, 2015, 116 : 4 - 4
  • [22] Active surveillance for intermediate-risk prostate cancer: yes, but for whom?
    Overland, Maya R.
    Washington, Samuel L., III
    Carroll, Peter R.
    Cooperberg, Matthew R.
    Herlemann, Annika
    CURRENT OPINION IN UROLOGY, 2019, 29 (06) : 605 - 611
  • [23] Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer
    Diven, Marshall A.
    Tshering, Lhaden
    Ma, Xiaoyue
    Hu, Jim C.
    Barbieri, Christopher
    McClure, Timothy
    Nagar, Himanshu
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [24] Outcomes for Men with Intermediate-risk Prostate Cancer on Active Surveillance
    Courtney, P. T.
    Deka, R.
    Cherry, D. R.
    Nelson, T. J.
    Luterstein, E.
    Salans, M. A.
    Yip, A. T. T.
    Nalawade, V.
    Parsons, J. K.
    Kader, K.
    Stewart, T. F.
    Rose, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S121 - S122
  • [25] Identifying intermediate-risk candidates for active surveillance of prostate cancer
    Savdie, Richard
    Aning, Jonathan
    So, Alan I.
    Black, Peter C.
    Gleave, Martin E.
    Goldenberg, S. Larry
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (10) : 605.e1 - 605.e8
  • [26] PROSTATE CANCER Time for active surveillance of intermediate-risk disease?
    Ahmed, Hashim U.
    NATURE REVIEWS UROLOGY, 2013, 10 (01) : 6 - 8
  • [27] Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer
    Cooperberg, Matthew R.
    Cowan, Janet E.
    Hilton, Joan F.
    Reese, Adam C.
    Zaid, Harras B.
    Porten, Sima P.
    Shinohara, Katsuto
    Meng, Maxwell V.
    Greene, Kirsten L.
    Carroll, Peter R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 228 - 234
  • [28] Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer
    Butler, Santino S.
    Mahal, Brandon A.
    Lamba, Nayan
    Mossanen, Matthew
    Martin, Neil E.
    Mouw, Kent W.
    Nguyen, Paul L.
    Muralidhar, Vinayak
    CANCER, 2019, 125 (18) : 3164 - 3171
  • [29] FOCAL CRYOTHERAPY FOR LOW- TO INTERMEDIATE-RISK PROSTATE CANCER: LONG TERM RESULTS AND MATCHED PAIR COMPARISON WITH ACTIVE SURVEILLANCE
    Marra, Giancarlo
    Soeterik, Timo
    Oreggia, Davide
    Pasquali, Caio
    Tourinho-Barbosa, Rafael
    Moschini, Marco
    Filippini, Claudia
    van Melick, Harm H. E.
    van den Bergh, Roderick C. N.
    Gontero, Paolo
    Cathala, Nathalie
    Macek, Petr
    Sanchez-Salas, Rafael
    Cathelineau, Xavier
    JOURNAL OF UROLOGY, 2021, 206 : E817 - E817
  • [30] Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer
    Kishan, Amar U.
    King, Christopher R.
    SEMINARS IN RADIATION ONCOLOGY, 2017, 27 (03) : 268 - 278